Loading...
XPARGBT
Market cap340mUSD
Dec 24, Last price  
25.95EUR
1D
1.57%
1Q
-27.92%
Jan 2017
-63.55%
Name

Guerbet SA

Chart & Performance

D1W1MN
XPAR:GBT chart
P/E
13.73
P/S
0.41
EPS
1.89
Div Yield, %
1.93%
Shrs. gr., 5y
-0.14%
Rev. gr., 5y
0.03%
Revenues
796m
+5.63%
247,488,000269,477,000289,408,000305,548,000320,783,000335,479,000352,579,000377,834,000404,254,000390,596,000409,508,000489,914,000776,469,000808,630,000794,612,000816,906,000712,295,000732,071,000753,275,000795,654,000
Net income
24m
P
17,203,00023,014,00018,926,00023,762,00024,389,00020,495,0005,880,00014,427,00020,399,00020,489,00026,127,00039,923,00028,930,00046,219,00046,819,00037,328,00018,240,00032,637,000-41,116,00023,866,000
CFO
27m
+5.98%
32,129,00041,840,00010,417,00040,292,00031,646,00037,218,00037,038,00041,442,00044,632,00059,280,00059,976,00065,649,00038,687,00056,054,00076,923,000124,406,000115,542,000110,723,00025,889,00027,437,000
Dividend
Jul 01, 20240.5 EUR/sh
Earnings
May 23, 2025

Profile

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services. In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and SeQure and DraKon, which are microcatheters. Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. The company was founded in 1926 and is headquartered in Villepinte, France.
IPO date
Jan 15, 1986
Employees
2,839
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
795,654
5.63%
753,275
2.90%
732,071
2.78%
Cost of revenue
303,708
797,589
758,389
Unusual Expense (Income)
NOPBT
491,946
(44,314)
(26,318)
NOPBT Margin
61.83%
Operating Taxes
8,637
8,032
(8,830)
Tax Rate
1.76%
NOPAT
483,309
(52,346)
(17,488)
Net income
23,866
-158.05%
(41,116)
-225.98%
32,637
78.93%
Dividends
(6,310)
(10,733)
(8,814)
Dividend yield
Proceeds from repurchase of equity
592
BB yield
Debt
Debt current
9,539
33,611
33,847
Long-term debt
396,502
278,431
299,691
Deferred revenue
13,378
11,212
Other long-term liabilities
34,250
32,150
43,935
Net debt
339,018
250,140
205,012
Cash flow
Cash from operating activities
27,437
25,889
110,723
CAPEX
(41,555)
(50,523)
(48,931)
Cash from investing activities
(59,931)
(55,398)
(52,243)
Cash from financing activities
44,749
(43,994)
(36,033)
FCF
397,230
(149,696)
(389)
Balance
Cash
51,279
41,683
115,728
Long term investments
15,744
20,219
12,798
Excess cash
27,240
24,238
91,922
Stockholders' equity
378,272
367,796
393,318
Invested Capital
768,866
680,158
675,632
ROIC
66.71%
ROCE
61.07%
EV
Common stock shares outstanding
12,578
12,620
12,641
Price
Market cap
EV
EBITDA
553,091
16,482
29,627
EV/EBITDA
Interest
10,634
4,573
5,342
Interest/NOPBT
2.16%